A team from Baylor College of Medicine and Texas Children's Cancer Center led the study, which tested chimeric antigen ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

an immune-activating interleukin-15 superagonist also developed by ImmunityBio. The therapeutic promise of this vaccine approach is now being leveraged by ImmunityBio to advance a ‘personalized ...

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 are linked to a 35% lower rate of serious infections in older adults with psoriatic disease compared to other treatments.